Bellevue Group AG Has $1.27 Million Stock Position in Doximity, Inc. (NASDAQ:DOCS)

Bellevue Group AG lowered its holdings in Doximity, Inc. (NASDAQ:DOCS - Free Report) by 59.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 29,060 shares of the company's stock after selling 43,095 shares during the period. Bellevue Group AG's holdings in Doximity were worth $1,266,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in DOCS. FMR LLC boosted its position in Doximity by 30.5% during the 3rd quarter. FMR LLC now owns 6,837,733 shares of the company's stock worth $297,920,000 after purchasing an additional 1,598,602 shares during the period. William Blair Investment Management LLC boosted its position in shares of Doximity by 15.8% in the second quarter. William Blair Investment Management LLC now owns 6,404,068 shares of the company's stock worth $179,122,000 after buying an additional 873,682 shares during the period. Los Angeles Capital Management LLC boosted its position in shares of Doximity by 6,242.6% in the third quarter. Los Angeles Capital Management LLC now owns 650,874 shares of the company's stock worth $28,359,000 after buying an additional 640,612 shares during the period. Clearbridge Investments LLC grew its stake in shares of Doximity by 7.1% in the second quarter. Clearbridge Investments LLC now owns 5,853,035 shares of the company's stock valued at $163,709,000 after buying an additional 387,200 shares in the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Doximity by 23.1% during the 2nd quarter. Renaissance Technologies LLC now owns 1,603,202 shares of the company's stock valued at $44,842,000 after buying an additional 301,100 shares during the period. Hedge funds and other institutional investors own 87.19% of the company's stock.

Doximity Price Performance

Shares of DOCS traded down $0.39 during mid-day trading on Friday, hitting $53.00. The company's stock had a trading volume of 859,144 shares, compared to its average volume of 2,704,210. The firm has a 50-day moving average price of $45.86 and a 200 day moving average price of $36.09. Doximity, Inc. has a fifty-two week low of $22.96 and a fifty-two week high of $61.75. The stock has a market capitalization of $9.89 billion, a price-to-earnings ratio of 58.24, a PEG ratio of 4.25 and a beta of 1.30.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on DOCS. Raymond James reaffirmed an "outperform" rating and issued a $65.00 price objective (up previously from $37.00) on shares of Doximity in a research report on Friday, November 8th. JPMorgan Chase & Co. raised their price objective on Doximity from $30.00 to $48.00 and gave the stock a "neutral" rating in a research note on Thursday, November 21st. Robert W. Baird boosted their target price on shares of Doximity from $41.00 to $45.00 and gave the company an "outperform" rating in a research note on Tuesday, September 17th. Morgan Stanley raised shares of Doximity from an "underweight" rating to an "equal weight" rating and increased their target price for the stock from $33.00 to $53.00 in a report on Thursday, November 14th. Finally, KeyCorp raised shares of Doximity from a "sector weight" rating to an "overweight" rating and set a $70.00 price target for the company in a report on Friday, November 8th. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $52.27.

Doximity Company Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.